NHU(SZ:002001)2025-04-14 11:25Financial Performance - The company's operating revenue for 2024 reached ¥21,609,592,228.45, representing a 42.95% increase compared to ¥15,116,537,003.30 in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥5,868,545,988.62, a significant increase of 117.01% from ¥2,704,238,767.54 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥5,828,938,494.33, up 122.97% from ¥2,614,210,640.58 in the previous year[17]. - Basic earnings per share for 2024 were ¥1.91, reflecting a 119.54% increase from ¥0.87 in 2023[17]. - The company's total assets at the end of 2024 amounted to ¥42,989,132,470.97, a 9.79% increase from ¥39,156,246,864.67 at the end of 2023[17]. - The net assets attributable to shareholders increased by 18.22% to ¥29,324,997,728.95 from ¥24,804,662,320.99 in 2023[17]. - Cash flow from operating activities for 2024 was ¥7,073,064,183.33, a 38.16% increase compared to ¥5,119,370,863.32 in 2023[17]. - The weighted average return on equity rose to 21.78%, an increase of 10.54 percentage points from 11.24% in 2023[17]. Revenue Breakdown - Revenue from the pharmaceutical and chemical sector accounted for ¥19.84 billion, which is 91.82% of total revenue, with a year-on-year growth of 43.81%[59]. - The nutrition products segment generated ¥15.05 billion, making up 69.67% of total revenue, with a significant increase of 52.58% compared to the previous year[59]. - The company’s total revenue for 2024 reached ¥21.61 billion, representing a 42.95% increase compared to ¥15.12 billion in 2023[59]. - The company achieved a 54.57% increase in foreign sales, amounting to ¥12.05 billion, which represents 55.78% of total revenue[59]. Market Outlook - The global demand for methionine is projected to increase by 6.3% in 2024, with domestic demand in China expected to rise by 4.7%[28][29]. - The vitamin market in China is expected to produce approximately 420,000 tons in 2024, accounting for 85.9% of global production, with prices recovering from a low point[27]. - The revenue of the fragrance and flavor industry in China is expected to reach ¥50 billion by 2025, with significant export contributions[30]. Research and Development - The company maintained R&D investment at over 5% of revenue for several consecutive years, focusing on key technologies with strategic economic impact[47]. - The company is focusing on expanding its core technology platforms in the fine chemical industry, particularly in nutrition, flavors, and new materials[26]. - The company is advancing the development of continuous reaction and pipeline reaction technologies to enhance production efficiency and competitiveness[72]. - The company has successfully achieved the production of vitamins B5 and B12 through optimized fermentation processes, positioning itself at the forefront of green manufacturing[72]. - R&D investment reached ¥1,036,161,740.50 in 2024, marking a 16.71% increase from ¥887,801,475.02 in 2023, while the ratio of R&D investment to operating revenue decreased by 1.08 percentage points to 4.79%[74]. Environmental Compliance - The company has established a comprehensive wastewater treatment system, ensuring effective collection and incineration of wastewater to reduce emissions[185]. - The company is committed to higher environmental standards and exploring eco-friendly production methods in response to evolving environmental regulations[115]. - The company has successfully renewed pollution discharge permits for multiple subsidiaries, valid until 2029[180]. - All reported pollutants from the companies were within the regulatory limits, indicating compliance with environmental standards[182]. Governance and Management - The company emphasizes compliance and transparent information disclosure, ensuring all shareholders have equal access to information[126]. - The company has a robust organizational structure with independent operational departments, ensuring no overlap with the controlling shareholder's functions[134]. - The company has appointed independent directors with diverse backgrounds, including expertise in economics, management, and law, enhancing governance[143]. - The company has a clear performance guidance strategy for the upcoming fiscal year[148]. Employee and Shareholder Relations - The company distributed a cash dividend of 4.50 RMB per 10 shares, totaling 1,383,039,756.00 RMB (including tax) based on a share base of 3,073,421,680 shares[163]. - The company has a competitive compensation structure that includes basic salary, performance pay, and benefits, aimed at enhancing employee satisfaction and loyalty[161]. - The total remuneration for directors, supervisors, and senior management amounted to CNY 31.62 million[153]. Strategic Initiatives - The company plans to accelerate its internationalization strategy and enhance local operational capabilities to navigate macroeconomic uncertainties[110]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential deals[117]. - The company aims to strengthen its nutrition business, focusing on integrated and market-coordinated operations to enhance product competitiveness[102].